Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANATEE study of RO7204239 plus risdiplam in spinal muscular atrophy
2023-506761-65-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of emugrobart and risdiplam in spinal muscular atrophy (SMA) (6 arms), sponsored by Roche. Planned start Apr 2022; status: authorised.
02
Drugs
emugrobartrisdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2023-506761-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506761-65-00.